Key facts
- Notable investors include Hangzhou Capital, Betta Pharmaceuticals, Westlake University (Hangzhou) Equity Investment, Xinghua Dingli Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Groovy Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Groovy Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Groovy Medicine
Developer of an AI-driven drug discovery platform intended for the development of treatments for major diseases such as cancer and neurodegenerative disorders. The company's platform offers predictive modelling tools, compound screening systems, molecular simulation engines, disease-specific datasets, biomarker identification tools and target validation modules, enabling researchers to accelerate drug development and improve therapeutic outcomes.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2022
- Website
- groovymedicine.com/
- Ownership
- Privately Held (backing)
Groovy Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Groovy Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Groovy Medicine in its N-PORT filings yet. We sweep new filings monthly.